Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT03848052
Recruiting Observational

Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)

NCT03848052 · tracked via the Priya Life Science France tracker
Sponsor
UNICANCER
Phase
Observational
Started
2017-10-02
Last updated
2026-05-27

Condition(s) studied

Lung Cancer

Study summary

This database compiles data from existing data available from patient's electronic medical records (EMR) at the 38 participating hospitals (20 French comprehensive cancer centers and 18 public hospitals).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion criteria : * Adult (over 18) * Treated (with radiotherapy or systemic anti-cancer treatment) for a lung cancer or diagnosed with metastatic lung cancer over the selection period at one of the participating site Exclusion criteria \- None

Primary outcome measure(s)

  • Patient characteristics — Baseline
    Age in years, Tobacco consumption, other exposures, Legal recognition as occupational disease, Medical history, History of other cancer, weight in kg and performance status (ECOG)
  • Tumor characteristics — Baseline
    Staging, Tumor size, sampling Method, histological type
  • Treatment patterns — From Baseline until 2024 (yearly basis)
    Drug, therapeutic class, treatment duration at each n treatment line

Trial sites (21)

FacilityCityRegionStatus
Institut de Cancérologie de l'Ouest - Paul Papin Angers France Recruiting
Institut Bergonié Bordeaux France Recruiting
Centre François Baclesse Caen France Recruiting
Centre Jean Perrin Clermont-Ferrand France Recruiting
Hôpital Intercommunal de Créteil Créteil France Recruiting
Centre Georges-François Leclerc Dijon France Recruiting
Centre Oscar Lambret Lille France Recruiting
Centre Léon Bérard Lyon France Recruiting
Institut Paoli-Calmettes Marseille France Recruiting
Institut régional du Cancer Montpellier / Val d'Aurelle Montpellier France Recruiting
Groupe Hospitalier Région Mulhouse et Sud Alsace - Hôpital Emile Muller Mulhouse France Recruiting
Institut de cancérologie de l'Ouest - René Gauducheau Nantes France Recruiting
Centre Antoine Lacassagne Nice France Recruiting
Institut Curie Paris France Recruiting
Institut Jean Godinot Reims France Recruiting
Centre Henri Becquerel Rouen France Recruiting
Institut Curie - Hôpital René Huguenin Saint-Cloud France Recruiting
Centre Paul Strauss Strasbourg France Recruiting
Institut Claudius Regaud Toulouse France Recruiting
Institut de Cancérologie de Lorraine Vandœuvre-lès-Nancy France Recruiting
Institut Gustave Roussy Villejuif France Recruiting

More UNICANCER trials in France

Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases Starting soon
Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme Recruiting
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery Recruiting
Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer Active, not recruiting
Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer Active, not recruiting

Other trials for the same condition

Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer Recruiting
Is 3D Modeling From Non-contrast CT Accurate for Minimally Invasive Lung Segmentectomies ? Starting soon
Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients Recruiting
Interest of Intensive Postoperative Rehabilitation Following Minimally Invasive Lung Resection Recruiting
Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03848052 on ClinicalTrials.gov ↗ ← All trials in France